Literature DB >> 15366373

Response of TNF-hyporesponsive SPRET/Ei mice in models of inflammatory disorders.

Jan Staelens1, Leen Puimège, Tina Mahieu, Gwenda Pynaert, Tino Hochepied, Annelies Vandenabeele, Johan Grooten, Dimitris Kontoyiannis, Frans Van Roy, George Kollias, Claude Libert.   

Abstract

Most inflammatory disorders are becoming more prevalent, especially in Western countries. The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF) plays a prominent role in many of these inflammatory disorders. We have previously shown that SPRET/Ei mice exhibit an extreme and dominant resistance to high doses of TNF. In this report, we investigate the response of heterozygous (C57BL/6xSPRET/Ei)F1 mice in different models of inflammatory diseases. Compared with C57BL/6 mice, (B x S)F1 mice are protected against TNF-induced arthritis and are partially protected against allergic asthma in an ovalbumin-induced model. However, these mice display complete susceptibility to TNF-induced inflammatory bowel disease. These results indicate that the SPRET/Ei genome harbors potent dominant antiinflammatory genes that might be relevant for the treatment of certain chronic inflammatory diseases. It is very well possible that different genes are implicated in the different models.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15366373     DOI: 10.1007/s00335-004-3002-z

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  22 in total

Review 1.  TNF in the inflammatory response.

Authors:  D N Männel; B Echtenacher
Journal:  Chem Immunol       Date:  2000

Review 2.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Authors:  W J Sandborn; S B Hanauer
Journal:  Inflamm Bowel Dis       Date:  1999-05       Impact factor: 5.325

3.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 4.  The pathophysiology of tumor necrosis factors.

Authors:  P Vassalli
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

5.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

6.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies.

Authors:  D Kontoyiannis; M Pasparakis; T T Pizarro; F Cominelli; G Kollias
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

Review 7.  The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

Authors:  G Kollias; E Douni; G Kassiotis; D Kontoyiannis
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

8.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 9.  Asthma: an epidemic of dysregulated immunity.

Authors:  Dale T Umetsu; Jennifer J McIntire; Omid Akbari; Claudia Macaubas; Rosemarie H DeKruyff
Journal:  Nat Immunol       Date:  2002-08       Impact factor: 25.606

10.  Hyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumor necrosis factor and implications for a TNF-based antitumor therapy.

Authors:  Jan Staelens; Ben Wielockx; Leen Puimège; Frans Van Roy; Jean-Louis Guénet; Claude Libert
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

View more
  4 in total

Review 1.  Using the inbred mouse strain SPRET/EiJ to provide novel insights in inflammation and infection research.

Authors:  Steven Timmermans; Jolien Souffriau; Jolien Vandewalle; Lise Van Wyngene; Kelly Van Looveren; Tineke Vanderhaeghen; Claude Libert
Journal:  Mamm Genome       Date:  2018-06-09       Impact factor: 2.957

2.  Tumor necrosis factor inhibits glucocorticoid receptor function in mice: a strong signal toward lethal shock.

Authors:  Tom Van Bogaert; Sofie Vandevyver; Lien Dejager; Filip Van Hauwermeiren; Iris Pinheiro; Ioanna Petta; David Engblom; Anna Kleyman; Günther Schütz; Jan Tuckermann; Claude Libert
Journal:  J Biol Chem       Date:  2011-06-06       Impact factor: 5.157

3.  Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus.

Authors:  Kimberly L Mahler; Jessica L Fleming; Amy M Dworkin; Nicholas Gladman; Hee-Yeon Cho; Jian-Hua Mao; Allan Balmain; Amanda Ewart Toland
Journal:  BMC Genomics       Date:  2008-12-23       Impact factor: 3.969

4.  Schistosoma mansoni experimental infection in Mus spretus (SPRET/EiJ strain) mice.

Authors:  Luis Pérez del Villar; Belén Vicente; Purificación Galindo-Villardón; Andrés Castellanos; Jesús Pérez-Losada; Antonio Muro
Journal:  Parasite       Date:  2013-08-29       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.